The non-coding GBA1 rs3115534 variant is associated with REM sleep behavior disorder in Nigerians

Oluwadamilola O. Ojo; Sara Bandres-Ciga; Mary B. Makarious; Peter Wild Crea; Dena G. Hernandez; Henry Houlden; Mie Rizig; Andrew B. Singleton; Alastair J. Noyce; Mike A. Nalls; Cornelis Blauwendraat; Njideka U. Okubadejo; the Nigeria Parkinson’s Disease Research Network and the Global Parkinson’s Genetics Program (GP2)

doi:10.1101/2023.11.07.23298092

Abstract

Background Damaging coding variants in GBA1 are a genetic risk factor for rapid eye movement sleep behavior disorder (RBD), which is a known early feature of synucleinopathies. Recently, a population-specific non-coding variant (rs3115534) was found to be associated with PD risk and earlier disease onset in individuals of African ancestry.

Objectives To investigate whether the GBA1 rs3115534 PD risk variant is associated with RBD.

Methods We studied 709 persons with PD and 776 neurologically healthy controls from Nigeria. The GBA1 rs3115534 risk variant status was imputed from previous genotyping for all. Symptoms of RBD were assessed with the RBD screening questionnaire (RBDSQ).

Results The non-coding GBA1 rs3115534 risk variant is associated with possible RBD in individuals of Nigerian origin (Beta = 0.3640, SE = 0.103, P =4.093e-04), as well as after adjusting for PD status (Beta = 0.2542, SE = 0.108, P = 0.019) suggesting that this variant may have the same downstream consequences as GBA1 coding variants.

Conclusions We show that the non-coding GBA1 rs3115534 risk variant is associated with increased RBD symptomatology in Nigerians with PD. Further research is required to assess association with polysomnography-defined RBD.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; MAN participated as part of a competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research. MAN also currently serves on the scientific advisory board at Clover Therapeutics and is an advisor and scientific founder at Neuron23 Inc; no other relationships or activities that could appear to have influenced the submitted work.

Funding Statement

This work was supported in part by the Intramural Research Program of the National Institute on Aging (NIA) and the Center for Alzheimers and Related Dementias (CARD) within the Intramural Research Program of the NIA and the National Institute of Neurological Disorders and Stroke. Data used in the preparation of this article were obtained from Global Parkinsons Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinsons (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinsons Research (https://gp2.org). This work utilized the computational resources of the NIH HPC Biowulf cluster (https://hpc.nih.gov).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research ethics approval for the study was obtained from the National Health Research Ethics Committee (NHREC) in Nigeria, all participating institutions' health research and ethics committees in Nigeria and the University College London (UCL) Institutional Review Board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

This version of the manuscript has been revised to update the group and consortium author lists (NPDR and GP2 respectively).

Data Availability

All data used in this manuscript is available via GP2 at the https://www.amp-pd.org/portal.

https://www.amp-pd.org/

https://1drv.ms/x/s!Aj-0YTgBXcwfhJ9orGkbfhHqocIZEA

https://docs.google.com/spreadsheets/d/1dum-N2jBjW8DUzRjg2z_VGgJ0WPsSOZ8/edit#gid=1769939610

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.